# C. Lance Cowey

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/c-lance-cowey/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,419 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 32 |
| i10-index | 56 |
| Last Known Institution | Texas Oncology |
| OpenAlex ID | https://openalex.org/A5025809703 |
| ORCID iD | https://orcid.org/0000-0001-8597-8486 |
| Works | 111 |

## Researcher papers

- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Researcher university

- [Texas Oncology](https://scholariq.org/institutions/texas-oncology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.